Lymphoblastic lymphoma following prenatal exposure to phenytoin

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 2, 1996, Pages 241-243

  Murray, Jeffrey C ^a,b   Hill, Reba Michels ^a   Hegemier, Suzanne ^a   Hurwitz, Richard L ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b Cook Children's Medical Center ^*  (United States)

Author keywords

fetal hydantoin syndrome; oncogenesis; phenytoin; prenatal exposure

Indexed keywords

PHENYTOIN;

ARTICLE; CARCINOGENESIS; CASE REPORT; EPILEPSY; HUMAN; LYMPHOBLASTOMA; MALE; MEDIASTINUM TUMOR; META ANALYSIS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOMA, LYMPHOBLASTIC; MALE; PHENYTOIN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 0029999712     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199605000-00033     Document Type: Article

References (23)

1. Pendergrass TW, Hanson JW. Fetal hydantoin and neuroblastoma. Lancet 1976;2:150.
2. Sherman S, Roizen N. Fetal hydantoin syndrome and neuroblastoma. Lancet 1976;2:517.
3. Blattner WA, Henson DE, Young RC, et al. Malignant mesenchymoma and birth defects: prenatal exposure to phenytoin. JAMA 1977;238:334-5.
4. Allen RW, Ogden B, Bentley FL, et al. Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. JAMA 1980;244:1464-5.
5. Jiminex JF, Seibert RW, Char F, et al. Melanotic neuroectodermal tumor of infancy and fetal hydantoin syndrome. Am J Pediatr Hematol Oncol 1981;3:9-15.
6. Bostrom B, Nesbit Jr ME. Hodgkin disease in a child with fetal alcohol-hydantoin syndrome. J Pediatr 1983; 103:760-2.
7. Lipson A, Bale P. Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone. Cancer 1985;55:1859-962.
8. Koren G, Demitrakoudis D, Weksberg R, et al. Neuroblastoma after prenatal exposure to phenytoin: cause and effect? Teratol 1989;40:157-62.
9. Al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci 1992;19:243-5.
10. Cohen MM. Neoplasia and the fetal alcohol and hydantoin syndromes. Neurobehav Toxicol Teratol 1981;3:161-2.
11. MacKinney AA, Booker HE. Diphenylhydantoin effects on human lymphocytes in vitro and in vivo. Arch Intern Med 1972;129:988-92.
12. Andrade-Mena CE, Sardo-Olmedo JAJ, Ramirez-Lizardo EJ. Effects of phenytoin administration on murine immune function. J Neuroimmunol 1994;50:3-7.
13. Miller RW. Relationship between human teratogens and carcinogens. J Natl Cancer Inst 1977;58:471-4.
14. Hanson JW. Fetal hydantoin effects. In: Sever JL, Brent RL, eds. Teratogen update: environmentally induced birth defect risks. New York: Alan R. Liss, 1986:29-33.
15. Sholler GF, Hawker RE, Nunn GR, et al. Primary left ventricular rhabdomyosarcoma in a child: noninvasive assessment and successful resection of a rare tumor. J Thorac Cardiovasc Surg 1987;93:465-72.
16. Li FP, Willard DR, Goodman R, et al. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer 1975;36:1359-62.
17. Basaran N, Kansu E, Hincal F. Serum immunoglobulins, complement levels and lymphocyte subpopulations in phenytoin-treated epileptic patients. Immunopharmacol Immunotoxicol 1989;11:335-46.
18. Burks AW, Charlton R, Casey P, et al. Immune function in patients treated with phenytoin. J Child Neurol 1989;4:25-9.
19. Jerina DM, Daly JW. Arene oxides: a new aspect of drug metabolism. Science 1974;185:573-82.
20. Buehler BA, Delimont D, van Waes M, et al. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990;322:1567-72.
21. Seeler RA, Israel JN, Royal JE, et al. Ganglioneuroblastoma and fetal hydantoin-alcohol syndromes. Pediatr 1979;63:524-7.
22. Taylor WF, Myers M, Taylor WR. Extrarenal Wilms' tumor in an infant exposed to intrauterine phenytoin. Lancet 1980; 1:481-2.
23. Ehrenbard LT, Chaganti RSK. Cancer in the fetal hydantoin syndrome. Lancet 1981;1:97.